Non-peptide drug conjugate (NDC) platform linking SST2 agonists with cytotoxic payloads via cleavable linkers for targeted delivery to SST2-expressing tumor cells; focus on neuroendocrine tumors and other SST2-positive solid tumors including SCLC, meningioma, head and neck cancer, and breast cancer

Targets: SST2, somatostatin receptor 2

Biotech Distilled coverage (9)

2026-08-28 UPDATE: Crinetics Pharmaceuticals (CRNX) - The Last Condition Falls
2026-08-15 UPDATE: Crinetics Pharmaceuticals (CRNX) - The Antitrust Gate Opens
2026-08-04 UPDATE: Crinetics Pharmaceuticals (CRNX) - The Last Quarter as a Public Company
2026-07-06 UPDATE: Crinetics Pharmaceuticals (CRNX) - Vertex Pays $10 Billion for the Pipeline-in-a-Pill
2026-06-15 UPDATE: Crinetics Pharmaceuticals (CRNX) — The ENDO Data Dump
2026-05-09 UPDATE: Crinetics Pharmaceuticals (CRNX) — Sell-the-News Decoded 🔒 Paid
2026-05-08 UPDATE: Crinetics Pharmaceuticals (CRNX) — The Q1 Print Lands in the Bull Range 🔒 Paid
2026-04-28 UPDATE: Crinetics Pharmaceuticals (CRNX) — The EC Catalyst Hits 🔒 Paid
2026-04-02 Crinetics Pharmaceuticals (CRNX) - Scientific Deep Dive for Paltusotine and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.